Compare Amphastar Pharmaceuticals Inc (AMPH) vs KeyCorp (KEY) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

KeyCorp (KEY) trades at $23.30, up 0.87% on the day, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.42. Revenue rebounded to $7.29 billion in 2025, driving net income to $1.83 billion. Analyst consensus is strongly positive, with a $29.32 price target representing significant upside. Recent news highlights a new $3 billion share buyback program and innovations in business fraud protection.

The outlook for KEY is favorable, supported by earnings momentum, shareholder returns, and analyst optimism. Key opportunities include continued earnings beats and capital return initiatives. Risks involve volatile cash flows, with net cash flow negative in 2025 and 2026, and sensitivity to interest rate changes affecting bank profitability.